The New Drug Conditional Approval Process in China: Challenges and Opportunities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The New Drug Conditional Approval Process in China: Challenges and Opportunities

Published:2017-05 Issue:5 Volume:39 Page:1040-1051
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Yao Xuefang,Ding Jinxi,Liu Yingfang,Li Penghui

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. The impact of reform of Chinese new drug registration and approval system on impact on new drug research and development;Yang;Modern Business Trade Industry,2012

2. Comparison and Reference of Foreign Expedited Approach for New Drug review;Xuefang;Chinese Pharmaceutical Journal,2016

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis;BMJ Global Health;2024-04

2. Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021;Clinical Therapeutics;2023-11

3. Review time of oncology drugs and its underlying factors: an exploration in China;Frontiers in Pharmacology;2023-11-01

4. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022;eClinicalMedicine;2023-09

5. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China;Therapeutic Innovation & Regulatory Science;2023-08-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP